Results 71 to 80 of about 47,712 (207)

Antihypertensive Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists

Cardiology Discovery
An increasing body of evidence shows that new antidiabetic drugs—particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists—have a beneficial effect on cardiovascular outcome.
Marijana Tadic, Cesare Cuspidi
doaj   +1 more source

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

Obesity Pillars
Aim: Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clinical
Haoyang Guo, Juan Yang, Jihan Huang, Ling Xu, Yinghua Lv, Yexuan Wang, Jiyuan Ren, Yulin Feng, Qingshan Zheng, Lujin Li   +9 more
doaj   +1 more source

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly [PDF]

, 2016
PURPOSE: Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension.
Silverstein, Julie M
core   +2 more sources

Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

International Journal of General Medicine, 2013
John Gerich Department of Medicine, Endocrine/Metabolism Division, University of Rochester School of Medicine, Rochester, NY, USA Abstract: Postprandial plasma glucose concentrations are an important contributor to glycemic control.
Gerich J
doaj  

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Cardiovascular Diabetology, 2018
Background Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management.
Ghadeer K. Dawwas, Steven M. Smith, Haesuk Park   +2 more
doaj   +1 more source

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. [PDF]

, 2014
It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed ...
Akiyama, Taro E, Armando, Aaron M, Bogner-Strauss, Juliane G, Chi, Tyler J, Chung, Heekyung, Cox, Jason M, Di Salvo, Jerry, Evans, Ronald M, Hah, Nasun, Lackey, Denise, Lagakos, William S, McNelis, Joanne, Oh, Da Young, Olefsky, Jerrold M, Pessentheiner, Ariane R, Powels, Mary Ann, Quehenberger, Oswald, Sasik, Roman, Sinz, Christopher, Walenta, Evelyn, Watkins, Steven M   +20 more
core   +1 more source

Mono-ADP-ribosyltransferase as a Potential Pharmacological Drug Target in the GLP-1 Based Therapy of Obesity and Diabetes Mellitus Type 2

Acta Chimica Slovenica, 2013
Glucagon-like peptide-1 (GLP-1) based therapy is well established for treating diabetes mellitus type 2. Moreover, GLP-1 receptor agonists influence weight loss, and have potential for treating obesity.
Aljoša Bavec
doaj  

Retatrutide-Induced Intractable Diarrhea

Annals of Internal Medicine: Clinical Cases
Gastrointestinal symptoms accompanying the use of glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide receptor-GLP-1 receptor co-agonists have been extensively catalogued.
Opeyemi Komolafe
doaj   +1 more source

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]

, 2014
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core   +1 more source

Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus [PDF]

Pharmacia
In recent years, incretin mimetics have become an important part of type 2 diabetes mellitus therapy. The aim of this study is to evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists.
Lora Petrova, Kalina Andreevska, Iva Parvova, Valentina Petkova   +3 more
doaj   +3 more sources